[A case of hepatitis B virus/human immunodeficiency virus coinfection in a patient who achived hepatitis B surface antigen seroclearance after interferon therapy followed by antiretroviral therapy without developing immune reconstitution inflammatory syndrome].
Coinfection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) is common worldwide. The current guidelines for the treatment of HIV infection recommend that HIV patients coinfected with HBV receive antiretoroviral therapy (ART) with two nucleoside analogs against HBV. However, an increase in liver enzymes that is usually attributed to HBV immune reconstitution inflammatory syndrome (IRIS) sometimes occurs in HBV/HIV-coinfected patients after the commencement of ART. We report a case of HBV/HIV-coinfection in which the chronic hepatitis B was successfully treated using interferon (IFN) therapy followed by ART without the development of IRIS. A Japanese man in thirties was referred to our hospital because of an acute HIV infection two months after the diagnosis of an acute HBV infection, which had progressed to a chronic HBV infection. The laboratory test results were as follows:hepatitis B surface antigen (HBsAg) positive, hepatitis B e antigen (HBeAg) positive, HBV DNA level of 8.8 Log copies/mL, HBV genotype A, alanine aminotransferase of 834 IU/L, HIV RNA level of 5 Log copies/mL, and a CD4+ T cell count of 437/microL. The initial treatment was natural IFNalpha therapy for chronic hepatitis B, and HBeAg seroclearance was achieved 20 weeks after the start of therapy. Four months after the end of IFN therapy for 24 weeks, ART including tenofovir and emtricitabine against HBV was commenced. Six months after starting ART, the patient's serum HBV DNA level had decreased and become undetectable and HBsAg seroclearance was achieved without an elevation in liver enzymes. The present case suggests that IFN therapy prior to ART contributes to a successful outcome for chronic hepatitis B patients coinfected with HIV, if the HIV status does not require the immediate start of ART.
Department of General Internal Medicine, Kyushu University Hospital.
Fujiko
F
Mitsumoto
Masayuki
M
Murata
Hiroaki
H
Ikezaki
Eiichi
E
Ogawa
Hiroaki
H
Taniai
Kazuhiro
K
Toyoda
Shigeru
S
Otaguro
Mosaburo
M
Kainuma
Kyoko
K
Okada
Norihiro
N
Furusyo
Jun
J
Hayashi
D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D060085:Coinfection; D015658:HIV Infections / Q000150:complications* / Q000628:therapy*; D006511:Hepatitis B Antigens / Q000032:analysis*; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008297:Male
D044966:Anti-Retroviral Agents; D006511:Hepatitis B Antigens; D007372:Interferons